Status:
ACTIVE_NOT_RECRUITING
REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18-130 years
Brief Summary
Acalabrutinib received European Medicines Agency approval on November 2020 for for CLL adult patients, either as monotherapy or in combination with obinutuzumab, in previously untreated patients or as...
Eligibility Criteria
Inclusion
- Adult patients (age \>18 years) with confirmed diagnosis of chronic lymphocytic leukemia/ small lymphocytic lymphoma
- Patients initiating front-line or subsequent treatment with acalabrutinib between January 2023 and Dec 2024 according to the national therapeutic protocol
- Patients able and willing to provide their written informed consent to participate in the study
Exclusion
- The treatment with acalabrutinib was initiated during an interventional clinical trial
- Enrolment performed less than 30 days from start of treatment with acalabrutinib
Key Trial Info
Start Date :
December 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2028
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06170671
Start Date
December 13 2023
End Date
September 30 2028
Last Update
December 22 2025
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Piteşti, Argeş, Romania, 110084
2
Research Site
Oradea, Bihor County, Romania, 410469
3
Research Site
Cluj-Napoca, Cluj, Romania, 400015
4
Research Site
Craiova, Dolj, Romania, 200143